Syneos Health, Inc. SYNH
We take great care to ensure that the data presented and summarized in this overview for Syneos Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SYNH
View all-
Pictet Asset Management Sa Geneva 73, V8640KShares$00.03% of portfolio
-
Eaton Vance Management Boston, MA61.1KShares$00.0% of portfolio
-
Brinker Capital Investments, LLC14.5KShares$00.01% of portfolio
-
Kula Investments, LLC Chicago, IL8.97KShares$00.08% of portfolio
-
Private Capital Group, LLC3.69KShares$00.2% of portfolio
-
Fieldpoint Private Securities, LLC2.47KShares$00.05% of portfolio
-
Wipfli Financial Advisors Llc,655Shares$00.0% of portfolio
-
Endurance Wealth Management, Inc.70Shares$00.0% of portfolio
-
Four Thought Financial, LLC Venice, FL53Shares$00.0% of portfolio
-
Urban Wealth Management, LLC19Shares$00.0% of portfolio
Latest Institutional Activity in SYNH
Top Purchases
Top Sells
About SYNH
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Insider Transactions at SYNH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Donna Hildebrand Kralowetz EVP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,288
-57.14%
|
$447,048
$21.5 P/Share
|
|
Sep 28
2023
|
John M. Dineen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,492
-91.16%
|
$577,332
$21.5 P/Share
|
|
Sep 28
2023
|
Barbara W. Bodem Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,385
-71.0%
|
$176,085
$21.5 P/Share
|
|
Sep 28
2023
|
Bernadette Connaughton Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,778
-83.55%
|
$310,338
$21.5 P/Share
|
|
Sep 28
2023
|
William E Klitgaard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,370
-100.0%
|
-
|
|
Sep 28
2023
|
Kenneth F Meyers Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,010
-90.28%
|
$525,210
$21.5 P/Share
|
|
Sep 28
2023
|
Matthew E. Monaghan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,640
-90.13%
|
$517,440
$21.5 P/Share
|
|
Sep 28
2023
|
David S. Wilkes Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,836
-75.28%
|
$206,556
$21.5 P/Share
|
|
Sep 28
2023
|
Alfonso G Zulueta Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,356
-70.9%
|
$175,476
$21.5 P/Share
|
|
Sep 28
2023
|
Michelle Keefe Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
193,442
-59.29%
|
$4,062,282
$21.5 P/Share
|
|
Sep 28
2023
|
Michael Lee Brooks Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,410
-100.0%
|
$146,630
$43.0 P/Share
|
|
Sep 28
2023
|
Michael Lee Brooks Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
122,033
-56.11%
|
$2,562,693
$21.5 P/Share
|
|
Sep 28
2023
|
Michael J. Bonello Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,433
-100.0%
|
-
|
|
Sep 28
2023
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,626
-61.12%
|
$1,357,146
$21.5 P/Share
|
|
Sep 28
2023
|
Christian Tucat Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,644
-61.2%
|
$1,063,524
$21.5 P/Share
|
|
Aug 31
2023
|
Michael Lee Brooks Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,615
-51.46%
|
-
|
|
Jul 17
2023
|
Donna Hildebrand Kralowetz EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-1.1%
|
$9,912
$42.29 P/Share
|
|
Jul 17
2023
|
Michael J. Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,433
+50.0%
|
-
|
|
Jun 15
2023
|
Christian Tucat Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
220
-0.44%
|
$9,020
$41.81 P/Share
|
|
May 25
2023
|
Alfonso G Zulueta Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,863
+36.79%
|
-
|